Penumbra (PEN) Preferred Stock Liabilities (2014)
Penumbra (PEN) reported Preferred Stock Liabilities of $111.5 million for Q4 2014.
Penumbra (PEN) has 1 years of Preferred Stock Liabilities data on file, last reported at $111.5 million in Q4 2014.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $111.5 million in Q4 2014, while the trailing twelve-month figure through Dec 2014 was $111.5 million (changed N/A YoY) and the FY2014 annual result came in at $111.5 million, up 98.26% from the prior year.
- Preferred Stock Liabilities was little changed at $111.5 million in Q4 2014 per PEN's latest filing.
- Across five years, Preferred Stock Liabilities topped out at $111.5 million in Q4 2014 and bottomed at $111.5 million in Q4 2014.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | - |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | - |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | - |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | - |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | - |
| 10 | Penumbra | 12.52 Bn | 11.91 Bn | 253.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2014 | 111.47 Mn |